Is this the right energy stock to generate dividend income: Emera Inc. (XTSE:EMA)?

Is this the right energy stock to generate dividend income: Emera Inc. (XTSE:EMA)?

ByMarketFacts

Emera Inc. (XTSE: EMA) is a geographically diverse energy and services company with interests in electricity generation, transmission, and distribution, as well as gas transmission and utility energy services. The company operates in five reportable segments throughout North America and the Caribbean: Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Others. The Florida Electric Utility comprises Tampa Electric, an electric utility serving customers in West Central Florida that is vertically integrated and regulated. The Company’s subsidiaries are Grand Bahama Power Company and Barbados Light & Power Company. The Company also owns St. Lucia Electricity Services Limited and Emera Caribbean Renewables Limited.

The Future of Cannabis!

The Future of Cannabis!

ByMarketFacts

Cannabis sales in the U.S. are expected to exceed $33 million in 2022 and reach $52 billion by the end of 2026, according to industry analysis. With market uncertainty lingering, some investors around the world are getting discouraged due to recurring losses in almost all sectors. However, investors with a long-term perspective see this situation as a great investment opportunity.

Among other fast-growing industries, including healthcare, technology, finance and more, cannabis is one industry with great potential for growth.

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

ByMarketFacts

Y-mAbs Therapeutics Inc. (XNAS: YMAB), incorporated in 2015 and headquartered in New York is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.

The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA, which targets tumors that express GD2, and one product candidate at the registration stage, OMBLASTYS, which targets tumors that express B7-H3.

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

ByMarketFacts

Blink Charging Co. (XNAS: BLNK) provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. The Company was founded in 2009 and is headquartered in Miami Beach, Florida.

Blink offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. The company offers its services through direct sales force and resellers, as well as sells residential Level 2 chargers through various internet channels.

Invest in your future by investing in Artificial Intelligence sector

Invest in your future by investing in Artificial Intelligence sector

ByMarketFacts

Artificial Intelligence is continuously innovating our industries and changing the way we live. It is no secret that anything that attracts attention and becomes an innovation quickly penetrates the stock market.

The United States has around 2000 AI companies in total. Last year, the global artificial intelligence market was valued at $93.5 billion and is expected to grow at 38% annually through 2030.

Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

ByMarketFacts

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

What Is Equity Research and Why Is It Important?

What Is Equity Research and Why Is It Important?

ByMarketFacts

There are many uncertainties surrounding the stock market, so investing in stocks has always been seen as a gamble. It is a common misconception in the stock market that success depends entirely on chance. A miracle may bring instant riches; a catastrophe may ruin all your hard work.

Everything is true to an extent, but equity research comes into play to protect people from the uncertainties of the stock market. Equity research acts as a timely and effective shield, ensuring the protection of investors.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

ByMarketFacts

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

ByMarketFacts

Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.

Is ESI a good opportunity for investors seeking growth: Element Solutions Inc (NYSE: ESI)?

Is ESI a good opportunity for investors seeking growth: Element Solutions Inc (NYSE: ESI)?

ByMarketFacts

Element Solutions Inc. (XYNS: ESI) is a global diversified specialty chemicals company focused on providing innovative solutions across several large and growing end-markets that enhance the products of everyday life. Developed in multi-step technological processes, the company’s innovative solutions enable the customers’ manufacturing processes in several key segments, including electronic circuitry, communication infrastructure, automotive systems, industrial surface finishing, consumer packaging, and offshore energy. With a long-standing presence in automotive markets and a deep market expertise in electronics, it sits at the intersection of this fast-growing market.